DelveInsight’s “Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hypertrophic Cardiomyopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hypertrophic Cardiomyopathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hypertrophic Cardiomyopathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hypertrophic Cardiomyopathy: An Overview
Hypertrophic Cardiomyopathy (HCM) is a common genetically inherited heart disease and represents an important cause of cardiovascular morbidity and mortality in patients of all ages. HCM is characterized by left ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical, with the most severe hypertrophy involving the basal interventricular septum.
Mutations in over a dozen genes encoding sarcomere-associated proteins cause HCM. MYH7 and MYBPC3, encoding the β-myosin heavy chain and myosin-binding protein C, respectively, are the two most common genes involved, together accounting for ~50% of the HCM families.
Despite the presence of cardiac hypertrophy, patients with HCM are commonly asymptomatic or minimally symptomatic. The most frequent symptoms result from four major pathophysiologic conditions: diastolic ventricular dysfunction, obstruction to LVOT, an imbalance between myocardial oxygen supply and demand, and cardiac arrhythmias. The onset of symptoms can occur at any age; typically, symptoms begin between the ages of 20 and 40.
Hypertrophic Cardiomyopathy Market Key Facts
In 2022, EU4 and the UK accounted for 120,389 diagnosed cases, which is estimated to increase during the forecast period (2023–2032).
Among EU4 countries and the UK, Germany had the highest number of diagnosed cases of HCM, which were 31,065 diagnosed cases in 2022 making up 26% of the total EU4 and the UK diagnosed cases.
According to the estimates, there were 76,795 and 38,397 cases of obstructive HCM (HOCM) and non-obstructive HCM (HNCM) cases respectively in 2022 in the US.
As per assessments by DelveInsight analysts, there were 2,811 diagnosed cases of Obstructive HCM (HOCM), and 1,405 diagnosed cases of Non-obstructive HCM (HNCM) in 2022 in Japan.
The estimated total diagnosed cases of HCM in the 7MM were 239,797 in 2022. The highest diagnosed cases of HCM were accounted for by the US in 2022 which were approximately 48% of the 7MM. These cases are expected to increase during the forecast period (2023–2032).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hypertrophic Cardiomyopathy pipeline therapies. It also thoroughly assesses the Hypertrophic Cardiomyopathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hypertrophic Cardiomyopathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hypertrophic Cardiomyopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hypertrophic Cardiomyopathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hypertrophic Cardiomyopathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hypertrophic Cardiomyopathy Epidemiology, Segmented as –
Prevalent Cases of Hypertrophic Cardiomyopathy [2019–2032]
Diagnosed Cases of Hypertrophic Cardiomyopathy [2019–2032]
Gender-specific Diagnosed Cases of Hypertrophic Cardiomyopathy[2019–2032]
Type-specific Diagnosed Cases of Hypertrophic Cardiomyopathy [2019–2032]
Hypertrophic Cardiomyopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hypertrophic Cardiomyopathy market or expected to be launched during the study period. The analysis covers the Hypertrophic Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hypertrophic Cardiomyopathy drugs based on their sale and market share.
The report also covers the Hypertrophic Cardiomyopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hypertrophic Cardiomyopathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hypertrophic Cardiomyopathy Market Will Evolve and Grow by 2032 @
Hypertrophic Cardiomyopathy Therapeutics Analysis
The current pharmacological treatment strategies of HCM are mainly centered on managing and minimizing the symptoms. Pharmacotherapy is the most frequently used therapy for HCM, mostly obstructive HCM. The clinical intention is to manage symptoms related to LVOT obstruction. The mainstay of the therapy is a combination of three types of drugs: β-adrenergic antagonists, calcium channel blockers, and antiarrhythmic drugs.
On the other hand, the focus of non-pharmacologic therapy is to treat obstructive HCM. The therapy is uncommon, indicated in a few obstructive HCM patients to control symptoms associated with LVOT obstruction. Non-pharmacologic therapy usually includes surgical myectomy, alcohol septal ablation, or dual-chamber pacing and is indicated for HCM patients with refractory symptoms after pharmacotherapy.
Several major pharma and biotech companies are developing therapies for Hypertrophic Cardiomyopathy. Currently, Cytokinetics is leading the therapeutics market with its Hypertrophic Cardiomyopathy drug candidates in the most advanced stage of clinical development.
Hypertrophic Cardiomyopathy Companies Actively Working in the Therapeutics Market Include
Lexeo Therapeutics, Inc.
And Many Others
Emerging and Marketed Hypertrophic Cardiomyopathy Therapies Covered in the Report Include:
TN-201: Tenaya Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hypertrophic Cardiomyopathy Competitive Intelligence Analysis
4. Hypertrophic Cardiomyopathy Market Overview at a Glance
5. Hypertrophic Cardiomyopathy Disease Background and Overview
6. Hypertrophic Cardiomyopathy Patient Journey
7. Hypertrophic Cardiomyopathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hypertrophic Cardiomyopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypertrophic Cardiomyopathy Unmet Needs
10. Key Endpoints of Hypertrophic Cardiomyopathy Treatment
11. Hypertrophic Cardiomyopathy Marketed Therapies
12. Hypertrophic Cardiomyopathy Emerging Drugs and Latest Therapeutic Advances
13. Hypertrophic Cardiomyopathy Seven Major Market Analysis
14. Attribute Analysis
15. Hypertrophic Cardiomyopathy Market Outlook (In US, EU5, and Japan)
16. Hypertrophic Cardiomyopathy Companies Active in the Market
17. Hypertrophic Cardiomyopathy Access and Reimbursement Overview
18. KOL Views on the Hypertrophic Cardiomyopathy Market
19. Hypertrophic Cardiomyopathy Market Drivers
20. Hypertrophic Cardiomyopathy Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Elevate your market presence and strategy in the medical devices industry through our meticulous market research services, driving growth and precision in every decision @ Medical Devices Market
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States